(MENAFN- ProactiveInvestors)
() is now enrolling Australian patients into the clinical trial for its FANTOM bioresorbable scaffolds for the treatment of coronary artery disease.
This is in addition to previously announced sites in Brazil and Europe.
The FANTOM II trial is enrolling patients to support a European CE Mark application which is expected to occur by mid-2016.
The scaffold made from REVA’s advanced proprietary polymer is designed to allow the restoration of blood flow in patients being treated for coronary artery disease then resorb from the body over time.
It was developed as an alternative to metal stents which are small tube-like devices permanently implanted into an artery to treat coronary artery disease.
Proactive Investors Australia is the market leader in producing news articles and research reports on ASX emerging companies with distribution in Australia UK North America and Hong Kong / China.
Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.